Targeted toward researchers in biochemistry, molecular and cell biology, pharmacology, and cancer, this is the second part of The Enzymes' volumes that discuss inhibitors of the Ras superfamily G-proteins.
Key features:
* Contributions from leading authorities
* Informs and updates on all the latest developments in the field
1. Cover image 2. Title page 3. Table of Contents 4. Copyright 5. Preface 6. Chapter One. Discovery of Small-Molecule Ras Inhibitors that Display Antitumor Activity by Interfering with Ras·GTP–Effector Interaction 7. Chapter Two. An Orthosteric Inhibitor of the RAS–SOS Interaction 8. Chapter Three. Conformation-Specific Inhibitors of Raf Kinases 9. Chapter Four. Inhibitors of the ERK Mitogen-Activated Protein Kinase Cascade for Targeting RAS Mutant Cancers 10. Chapter Five. Inhibiting the RAS–PI3K Pathway in Cancer Therapy 11. Chapter Six. The RalGEF/Ral Pathway: Evaluating an Intervention Opportunity for Ras Cancers 12. Chapter Seven. p21-Activated Kinase Inhibitors 13. Chapter Eight. Recent Progress in Developing Small Molecule Inhibitors Designed to Interfere with Ras Membrane Association: Toward Inhibiting K-Ras and N-Ras Functions 14. Chapter Nine. Synthetic Lethal Genetic Screens in Ras Mutant Cancers 15. Author Index 16. Subject Index
Targeted toward researchers in biochemistry, molecular and cell biology, pharmacology, and cancer, this is the second part of The Enzymes' volumes that discuss inhibitors of the Ras superfamily G-proteins.
Key features:
* Contributions from leading authorities
* Informs and updates on all the latest developments in the field
1. Cover image 2. Title page 3. Table of Contents 4. Copyright 5. Preface 6. Chapter One. Discovery of Small-Molecule Ras Inhibitors that Display Antitumor Activity by Interfering with Ras·GTP–Effector Interaction 7. Chapter Two. An Orthosteric Inhibitor of the RAS–SOS Interaction 8. Chapter Three. Conformation-Specific Inhibitors of Raf Kinases 9. Chapter Four. Inhibitors of the ERK Mitogen-Activated Protein Kinase Cascade for Targeting RAS Mutant Cancers 10. Chapter Five. Inhibiting the RAS–PI3K Pathway in Cancer Therapy 11. Chapter Six. The RalGEF/Ral Pathway: Evaluating an Intervention Opportunity for Ras Cancers 12. Chapter Seven. p21-Activated Kinase Inhibitors 13. Chapter Eight. Recent Progress in Developing Small Molecule Inhibitors Designed to Interfere with Ras Membrane Association: Toward Inhibiting K-Ras and N-Ras Functions 14. Chapter Nine. Synthetic Lethal Genetic Screens in Ras Mutant Cancers 15. Author Index 16. Subject Index
